FDA accepts protocols, endpoints for remaining phase 3 trials on PL9643 for dry eye

The FDA and Palatin Technologies have agreed on protocols and sign and symptom endpoints for the remaining phase 3 clinical trials of PL9643 for dry eye disease, the company announced in a press release.
“Current prescription options for DED are generally regarded as inadequate by many eye care professionals and patients due to low treatment efficacy, slow onset of action and/or poor tolerability,” Carl Spana, PhD, Palatin’s president and CEO, said in the release. “PL9643, with its early onset of efficacy for both signs and symptoms and its excellent ocular safety and

The FDA and Palatin Technologies have agreed on protocols and sign and symptom endpoints for the remaining phase 3 clinical trials of PL9643 for dry eye disease, the company announced in a press release.
“Current prescription options for DED are generally regarded as inadequate by many eye care professionals and patients due to low treatment efficacy, slow onset of action and/or poor tolerability,” Carl Spana, PhD, Palatin’s president and CEO, said in the release. “PL9643, with its early onset of efficacy for both signs and symptoms and its excellent ocular safety and